Dynamic Technology Lab’s Ocular Therapeutix OCUL Stock Holding History

Dynamic Technology Lab’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,814	Closed	-$44K	–	1396
2022 Q4	$44K	Buy	15,814 +2,540	+19%	+$8.41K	﹤0.01%	1027
2022 Q3	$55K	Buy	+13,274	New	+$66.9K	0.01%	1054
2021 Q4	–	Sell	-21,066	Closed	-$211K	–	1383
2021 Q3	$211K	Sell	21,066 -2,636	-11%	-$29.6K	0.03%	892
2021 Q2	$336K	Buy	23,702 +2,874	+14%	+$43.7K	0.03%	741
2021 Q1	$342K	Buy	+20,828	New	+$401K	0.04%	749
2020 Q4	–	Sell	-39,974	Closed	-$304K	–	1245
2020 Q3	$304K	Buy	+39,974	New	+$332K	0.05%	652
2020 Q2	–	Sell	-20,960	Closed	-$104K	–	1235
2020 Q1	$104K	Buy	+20,960	New	+$103K	0.02%	885
2019 Q1	–	Sell	-21,077	Closed	-$84K	–	1233
2018 Q4	$84K	Buy	+21,077	New	+$116K	0.01%	901
2017 Q2	–	Sell	-21,062	Closed	-$195K	–	1235
2017 Q1	$195K	Sell	21,062 -14,396	-41%	-$120K	0.05%	806
2016 Q4	$296K	Buy	+35,458	New	+$275K	0.08%	533

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dynamic Technology Lab's OCUL Position: Q1 2023 in Review

Dynamic Technology Lab sold out of Ocular Therapeutix (OCUL) in Q1 2023, closing a stake of 15,814 shares — an estimated $44K sold.

Dynamic Technology Lab first reported a position in OCUL in Q4 2016 and held it in 10 quarters. The position peaked at $342K in Q1 2021. 127 funds tracked by Wall St. Rank hold OCUL as of Q1 2023.

Dynamic Technology Lab reported no remaining Ocular Therapeutix position as of Q1 2023 after selling out during the quarter.
Dynamic Technology Lab sold 15,814 Ocular Therapeutix shares in Q1 2023, an estimated $44K.
Dynamic Technology Lab first reported a position in Ocular Therapeutix in Q4 2016 and held it in 10 quarters.
Dynamic Technology Lab's Ocular Therapeutix position peaked at $342K in Q1 2021.
127 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2023.

Based on Dynamic Technology Lab's 13F filing for Q1 2023, filed 12 May 2023.